PMID- 20558611
OWN - NLM
STAT- MEDLINE
DCOM- 20101206
LR  - 20210206
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 116
IP  - 17
DP  - 2010 Oct 28
TI  - How I treat acute myeloid leukemia.
PG  - 3147-56
LID - 10.1182/blood-2010-05-260117 [doi]
AB  - More than one quarter of a million adults throughout the world are diagnosed 
      annually with acute myeloid leukemia (AML). Despite considerable progress during 
      the past 3 decades in the therapy of AML, two-thirds of young adults and 90% of 
      older adults still die of their disease. The reported median age has increased 
      over the past few decades, mostly because of a greater willingness of physicians 
      to diagnose and treat older patients, and now is 72 years. The greatest challenge 
      is in this age group. However, much improvement in therapy is needed for all 
      adults with AML. Recent advances in allogeneic transplantation, a better 
      understanding of prognostic factors, and development of targeted agents have only 
      modestly improved overall outcome when large populations of patients are 
      considered. Although an explosion in knowledge about the molecular pathogenesis 
      of AML has outpaced treatment advances, such insights hold promise for the 
      development of new therapies directed at specific molecular abnormalities that 
      perturb malignant cell survival pathways. The current approach in 2010 to the 
      management of this disease is presented through a discussion of illustrative 
      cases.
FAU - Rowe, Jacob M
AU  - Rowe JM
AD  - Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, 
      Israel. rowe@jimmy.harvard.edu
FAU - Tallman, Martin S
AU  - Tallman MS
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20100617
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Cytogenetics
MH  - Female
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*diagnosis/drug therapy/genetics/*therapy
MH  - Male
MH  - Middle Aged
MH  - Remission Induction
MH  - Survival Analysis
MH  - Transplantation, Homologous
EDAT- 2010/06/19 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/06/19 06:00
PHST- 2010/06/19 06:00 [entrez]
PHST- 2010/06/19 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - S0006-4971(20)31178-2 [pii]
AID - 10.1182/blood-2010-05-260117 [doi]
PST - ppublish
SO  - Blood. 2010 Oct 28;116(17):3147-56. doi: 10.1182/blood-2010-05-260117. Epub 2010 
      Jun 17.